Targeting the LOX / hypoxia axis reverses many of the features that make pancreatic cancer deadly: inhibition of LOX abrogates metastasis and enhances drug efficacy-Reference-Cited by-同舟云学术

Targeting the LOX / hypoxia axis reverses many of the features that make pancreatic cancer deadly: inhibition of LOX abrogates metastasis and enhances drug efficacy

Published:2015-06-15 Issue:8 Volume:7 Page:1063-1076
ISSN:1757-4676
Container-title:EMBO Molecular Medicine
language:en
Short-container-title:EMBO Mol Med

Author:

Miller Bryan W¹,Morton Jennifer P¹,Pinese Mark²,Saturno Grazia³,Jamieson Nigel B⁴,McGhee Ewan¹,Timpson Paul²,Leach Joshua¹,McGarry Lynn¹,Shanks Emma¹,Bailey Peter⁵,Chang David⁵,Oien Karin⁵,Karim Saadia¹,Au Amy¹,Steele Colin¹,Carter Christopher Ross⁴,McKay Colin⁴,Anderson Kurt¹,Evans Thomas R Jeffry¹⁵,Marais Richard³,Springer Caroline⁶,Biankin Andrew⁵,Erler Janine T⁷,Sansom Owen J¹

Affiliation:

1. Cancer Research UK Beatson Institute Garscube Estate Glasgow UK

2. The Garvan Institute of Medical Research Sydney NSW Australia

3. Cancer Research UK Manchester Institute Withington Manchester UK

4. West of Scotland Pancreatic Unit Glasgow Royal Infirmary Glasgow UK

5. Institute of Cancer Sciences University of Glasgow Garscube Estate Glasgow UK

6. Institute of Cancer Research London UK

7. Biotech Research & Innovation Centre (BRIC) University of Copenhagen Copenhagen (UCPH) Denmark

Funder

Novo Nordisk Foundation (Hallas Møller Stipend)

Cancer Research UK

Pancreatic Cancer Research Fund